All In Biotech

Drug Trial Radar · NCT07463820

A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)

A Phase II Study of Combination Therapy With Luspatercept in Lower Risk Myelodysplasia: A Tier 1 MyeloMATCH Substudy

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Dec 18, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
NIH
First posted
Mar 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II MyeloMATCH treatment trial tests luspatercep with or without epoetin alfa or emavusertib for the treatment of low risk myelodysplasia and anemia. Biological therapies, such as luspatercep, use substances made from living organisms that may attack specific cancer cells and stop them from growing or kill them. Epoetin alfa is a substance that is made in the laboratory and stimulates the bone marrow to make red blood cells. Emavusertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving luspatercep with or without epoetin alfa or emavusertib may be effective for treating patients with low risk myelodysplasia and anemia.

Conditions

  • Myelodysplastic Syndrome

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • EmavusertibBiological

    Given PO

  • Epoetin AlfaBiological

    Given SC

  • LuspaterceptBiological

    Given SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Erythroid response rateTime frame: At 24 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.